Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Area of Science:

• Pharmacology
• Clinical Lipidology

Background:

• Ezetimibe is a cholesterol absorption inhibitor that reduces LDL-C in hypercholesterolemia.
• Fenofibrate is a lipid-lowering agent with established effects on triglycerides and other lipids.

Purpose of the Study:

• To evaluate the pharmacodynamic, pharmacokinetic, and safety profiles of ezetimibe and fenofibrate when administered alone and in combination.
• To assess the efficacy of co-administered ezetimibe and fenofibrate in reducing LDL-C and other lipid parameters.

Main Methods:

• A randomized, single-blind, placebo-controlled, parallel-group study involving 32 subjects with primary hypercholesterolemia.
• Subjects received fenofibrate 200 mg + ezetimibe 10 mg, fenofibrate 200 mg, ezetimibe 10 mg, or placebo daily for 14 days.
• Serum lipids were measured at baseline and on days 7 and 14; pharmacokinetic parameters were assessed on day 14.

Main Results:

• Co-administration of ezetimibe and fenofibrate significantly reduced LDL-C, total cholesterol, and triglycerides compared to monotherapy or placebo.
• Ezetimibe did not significantly alter fenofibrate pharmacokinetics.
• Fenofibrate increased ezetimibe Cmax and AUC, but this was not considered clinically significant due to ezetimibe's safety profile.

Conclusions:

• Combined ezetimibe and fenofibrate therapy yields superior LDL-C reduction compared to individual agents.
• The combination also demonstrated greater triglyceride reduction than fenofibrate alone.
• Co-administration is a potentially effective strategy for treating patients with mixed dyslipidemia.